Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High - Here's Why

Vaxcyte jumps on phase 3 data for pneumonia vaccine VAX-31

Vaxcyte jumps 32% on phase 3 VAX-31 vaccine data vs Prevnar 20 and Capvaxive. Read more here.

Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High - Here's Why

Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High - Here's What Happened

Vaxcyte shares surge as pneumococcal vaccine meets main trial ...

Vaxcyte Stock Hits New 52-Week High - Here’s Why - Vaxcyte (NASDAQ:PCVX)

Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.